Product Images Pemetrexed

This text contains a graph showing the Overall Sunvival (%) for different treatment arms over time in months, with the number of people at risk in each arm. The treatment arms are P+P4C, P4C, and P+C, which involve different combinations of Pemetrexed for Injection, pembrolizumab, and platinum chemotherapy, with or without placebo.*

This is a survival probability chart for two different chemotherapy treatments (Pemetrexed + Cisplatin and Gemcitabine + Cisplatin). The chart shows the number of patients at risk (12, 15, 18, 21, 2, 2) and their survival time in months. The data is split into two groups with corresponding curves representing the probability of survival over time for each treatment.*

This is a survival probability table comparing the effectiveness of two treatments, Pemetrexed+Cisplatin (PC) and Gomcitabine+Cisplatin (GC), over a period of 27 months. The table shows the survival time (in months) of patients receiving each treatment and the number of patients at risk for each time interval.*

This is a graph displaying the survival probability of patients who were given Pemetrexed versus those who received a placebo. The number of patients at risk is shown for each treatment group. The X-axis represents time in months, while the Y-axis represents the probability of survival. However, the graph is incomplete and some of the text is unreadable.*

This is a survival analysis table that shows the survival probability, patients at risk, and survival time (in months) for patients who were given either pemetrexed or placebo. It includes the number of patients at risk at specific points in time and the number of patients who survived. However, the output contains errors and unreadable characters, making the data unclear.*

This is a survival probability chart that compares the effectiveness of Pemetrexed and placebo for an unknown medical condition. The chart displays the number of patients at risk for each treatment group over time, as well as their survival time in months. There is not enough information to determine the exact medical condition being studied or to draw any conclusions about the effectiveness of these treatments.*

This appears to be a table displaying survival time in months for patients at risk who were given Pemetrexed + Cisplatin treatment. The table shows different time periods and the number of patients at risk for each period. It appears to be related to medical research.*

This text describes a medication called Pemetrexed. It is available in 100 mg vials for injection and is labeled as USP for injection.*

This is a product description of Pemetrexed for Injection, USP, available in vials of 500 mg. It is intended for intravenous use only and is a prescription-only medication. There are warnings on the label cautioning that it is a potent drug and should only be used under the guidance of a healthcare professional. The first few lines of the text may be a product code or reference number.*